SEARCH

SEARCH BY CITATION

Disclaimer: Supplementary materials have been peer-reviewed but not copyedited.

FilenameFormatSizeDescription
pmic7288-sup-0001-TableS1.doc4622K

Table S1. Clinical data of IgAN patients

Table S2. Clinical data of patients with membranous nephropathy

Table S3. Clinical data of patients with diabetic nephropathy

Table S4. Clinical data of patients with lupus nephropathy

Table S5. Clinical data of patients with focal and segmental glomerulosclerosis

Table S6. Clinical data of patients with non-glomerular disease

Figure S1. LG3 spot on 2-DE gels. Spots were visualized by colloidal blue staining. Four replicates for each of the six patients studied were performed and compared to four different controls. Three or four replicates were used for analysis by ImageMaster 2D Platinum, depending on the quality of the gels. Results were summarized on B).

Figure S2a. Peptide mass fingerprint of spot n°1 identified as LG3

Figure S2b. Mascot search result of spot 1 based on MS and MS/MS peptides and ion masses (I)

Figure S2c. Mascot search result of spot 1 based on MS and MS/MS peptides and ion masses (II)

Figure S3. Representative 2-DE Western blot of a healthy control and an IgAN patient. (A) α1-β-glycoprotein; (B) α1-antitrypsin and (C) LG3 fragment.

Figure S4. LG3 level measured by ELISA and normalized with proteinuria, A) or with urine creatinine, B).

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.